New biological therapies from the human genome

Bibliography

• LAWRENCE S: Biotech R&D goes further afield. Nat. Biotechnol. (2006) 24(9):1052.
   PubMed Web of Science ®Google Scholar
• GLASSMAN RH, SUN AY: Biotechnology: identifying advances from the hype. Nat. Rev. Drug Discov. (2004) 3:177-183.
   PubMed Web of Science ®Google Scholar
• WELLS TNC, PEITSCH MC: The chemokine information source: identification and characterisation of novel chemokines using the worldwideweb and expressed sequence tag databases. J. Leukoc. Biol. (1997) 61:545-550.
   PubMed Web of Science ®Google Scholar
• YEE DP, CONKLIN D: Automated clustering and assembly of large EST collections. Proceedings Sixth International Conference on Intelligent Systems for Molecular Biology (1998):203-211.
   Google Scholar
• ALTSCHUL SF, GISH W, MILLER W et al.: Basic local alignment search tool. J. Mol. Biol. (1990) 215:403-410.
   PubMed Web of Science ®Google Scholar
• KLEDAL TN, ROSENKILDE MM, COULIN F et al.: A broad-spectrum chemokine antagonist encoded by kaposi's sarcoma-associated herpesvirus. Science (1997) 277:1656-1659.
   PubMed Web of Science ®Google Scholar
• WELLS TNC, SCHWARTZ TW: Plagiarism of the host immune system: lessons about chemokine immunology from viruses. Curr. Opin. Biotechnol. (1997) 8(6):741-748.
   PubMed Web of Science ®Google Scholar
• KRAMER R, COHEN D: Functional genomics to new drug targets. Nat. Rev. Drug Discov. (2004) 3:965-972.
   PubMed Web of Science ®Google Scholar
• TASHIRO K, TADA H, HEILKER R et al.: Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science (1993) 261(5121):600-603.
   PubMed Web of Science ®Google Scholar
• WELLS TNC, GRABER P, PROUDFOOT AEI et al.: The three-dimensional structure of human interleukin-5 at 2.4-angstroms resolution: implication for the structures of other cytokines. Ann. NY Acad. Sci. (1994) 725:118-127.
   PubMed Web of Science ®Google Scholar
• FOSTER D, PARRISCH-NOVAK J, FOX B, XU W: Cytokine-receptor pairing: accelerating discovery of cytokine function. Nat. Rev. Drug Discov. (2004) 3:160-170.
   PubMed Web of Science ®Google Scholar
• GROSS JA, JOHNSTON J, MUDRI S et al.: TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature (2000) 404:995-999.
   PubMed Web of Science ®Google Scholar
• MILLER RT, JONES DT, THORNTON JM: Protein fold recognition by sequence threading: tools and assessment techniques. FASEB J. (1996) 10:171-178.
   PubMed Web of Science ®Google Scholar
• WAHAB HA, AHMAD KHAIRUDIN NB, SAMIAN MR et al.: Sequence analysis and structure prediction of type II Pseudomonas sp. USM 4-55 PHA synthase and an insight into its catalytic mechanism. BMC Struct. Biol. (2006) 6(1):23-37.
   PubMed Web of Science ®Google Scholar
• GRAVELEY BR: Alternative splicing: increasing diversity in the proteomic world. Trends Genet. (2001) 17(2):100-107.
   PubMed Web of Science ®Google Scholar
• BERTONE P, TRIFONOV V, ROZOWSKY JS et al.: Design optimization methods for genomic DNA tiling arrays. Genome Res. (2006) 16:271-281.
   PubMed Web of Science ®Google Scholar
• WASHIETL S, HOFACKER IL, LUKASSER M et al.: Mapping of conserved RNA secondary structures predicts thousands of functional noncoding RNAs in the human genome. Nat. Biotechnol. (2005) 23(11):1383-1390.
   PubMed Web of Science ®Google Scholar
• SCHEER A: Future trends in screening technology for drug discovery. Expert Opin. Drug Discov. (2006) 1(3):195-198.
   PubMed Web of Science ®Google Scholar
• SELVARAJU R, BERNASCONI L, LOSBERGER C et al.: Osteopontin is upregulated during in vivo demyelination and remyelination and enhances myelin formation in vitro. Mol. Cell. Neurosci. (2004) 25:707-721.
   PubMed Web of Science ®Google Scholar
• BESSON D, YEOW K, LANG P et al.: HTS and cellular biology at Serono.Curr. Drug Discov. (2003) 29-32.
   Google Scholar
• MALLAT Z, CORBAZ A, SCOAZEC A et al.: Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ. Res. (2001) 89:E41-E45.
   PubMed Web of Science ®Google Scholar
• BOLON B, GALBREATH E: Use of genetically engineered mice drug discovery and development: wielding occam's razor to prune the product portfolio. Int. J. Toxicol. (2002) 21(1):55-64.
   PubMed Web of Science ®Google Scholar
• ZAMBROWICZ BP, SANDS AT: Knockouts model the 100 best-selling drugs – will they model the next 100? Nat. Rev. Drug Discov. (2003) 2:38-51.
   PubMed Web of Science ®Google Scholar
• ZAMBROWICZ BP, SANDS AT: Modeling drug action in the mouse with knockouts and RNA interference. Drug Discov. Today (2004) 3(5):198-207.
   Google Scholar
• OHNO E, ONO K, KIKUCHI H et al.: Prolonged remission of adult T-cell leukemia/lymphoma treated with interferon-γ following autologous peripheral blood stem cell transplantation. Leuk. Lymph. (2005) 46(12):1843-1845.
   PubMed Web of Science ®Google Scholar
• PATEL VP, KREIDER BL, LI Y et al.: Molecular and functional characterization of two novel human C-C chemokines as inhibitors of two distinct classes of myeloid progenitors. J. Exp. Med. (1997) 185(7):1163-1172.
   PubMed Web of Science ®Google Scholar
• JANKOWSKI K, KUCIA M, WYSOCZYNSKI M et al.: Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behaviour of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res. (2003) 63:7926-7935.
   PubMed Web of Science ®Google Scholar
• KOZLOWSKI A, CHARLES SA, HARRIS JM: Development of pegylated interferons for the treatment of chronic hepatitis C. Biodrugs (2001) 15(7):419-429.
   PubMed Web of Science ®Google Scholar
• PLANK J, BODENLENZ M, SINNER F et al.: A double blind, randomised, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog Detemir. Diab. Care (2005) 28(5):1107-1112.
   PubMed Web of Science ®Google Scholar
• BERNKOP-SCHNURCH A, HOFFER MH, KAFEDJIISKI K: Thiomers for oral delivery of hydrophilic macromolecular drugs. Expert Opin. Drug Deliv. (2004) 1(1):87-98.
   PubMedGoogle Scholar
• ILLUM L: Nasal clearance in health and disease. J. Aerosol Med. (2006) 19(1):92-99.
   PubMedGoogle Scholar
• MOHLER KM, TORRANCE DS, SMITH CA et al.: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J. Immunol. (1993) 151:1548-1561.
   PubMed Web of Science ®Google Scholar
• DILLON SR, GROSS JA, ANSELL SM et al.: An APRIL to remember: novel TNF ligands as therapeutic targets. Nat. Rev. Drug Discov. (2006) 5(3):235-246.
   PubMed Web of Science ®Google Scholar
• PROUDFOOT AEI, POWER CA, HOOGEWERF AJ et al.: Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol. Chem. (1996) 271(5):2599-2603.
   PubMed Web of Science ®Google Scholar
• SIMMONS G, CLAPHAM PR, PICARD L et al.: Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science (1997) 276:276-279.
   PubMed Web of Science ®Google Scholar
• TONY H-P, SHEN B-J, REUSCH P et al.: Design of human interleukin-4 antagonists inhibiting interleukin-4-dependent and interleukin-13-dependent responses in T-cells and B-cells with high efficiency. Eur. J. Biochem. (1994) 225:659-665.
   PubMedGoogle Scholar
• McKINNON M, PAGE K, UINGS IJ et al.: An interleukin 5 mutant distinguishes between two functional responses in human eosinophils. J. Exp. Med. (1997) 186(1):121-129.
   PubMed Web of Science ®Google Scholar
• LABRIOLA-TOMPKINS E, CHANDRAN C et al.: Identification of the discontinuous binding site in human interleukin 1β for the type I interleukin 1 receptor. Proc. Natl. Acad. Sci. (1991) 88:11182-11186.
   PubMed Web of Science ®Google Scholar
• AKESON AL, WOODS CW, HSIEH LC et al.: AF12198, a novel low molecular weight antagonist, selectively binds the human type I interleukin (IL)-1 receptor and blocks in vivo responses to IL-1. J. Biol. Chem. (1996) 271(48):30517-30523.
   PubMed Web of Science ®Google Scholar
• HE MM, SMITH AS, OSLOB JD et al.: Small-molecule inhibition of TNF-a. Science (2005) 310(5750):1022-1025.
   PubMed Web of Science ®Google Scholar
• ARKIN MR, WELLS JA: Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. (2004) 3:301-317.
   PubMed Web of Science ®Google Scholar
• BILANCIO A, OKKENHAUG K, CAMPS M et al.: Key role of the p110d isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110d function in B cells. Blood (2006) 107(2):642-650.
   PubMed Web of Science ®Google Scholar
• MILLS J, NIEWMIERZYCKA A, OLOUMI A et al.: Critical role of integrin-linked kinase in granule cell precursor proliferation and cerebellar development. J. Neurosci. (2006) 26(3):830-840.
   PubMed Web of Science ®Google Scholar
• NG EW, SHIMA DT, CALIAS P et al.: Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. (2006) 5(2):123-132.
   PubMed Web of Science ®Google Scholar
• WHITE RR, SULLENGER BA, RUSCONI CP: Developing aptamers into therapeutics. JCI (2000) 106(8):929-934.
   Google Scholar
• GOPINATH S, MISONO T, KAWASAKI K et al.: An efficient RNA aptamer against human influenza B virus hemagglutinin. J. Biochem. (Tokyo) (2006) 139(5):837-846.
   PubMed Web of Science ®Google Scholar
• SAZANI P, KOLE R: Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. JCI (2003) 112:481-486.
   Google Scholar
• GROSS J, DILLON S, MUDRI S et al.: TACI-Ig neutralizes molecules critical for B cell development and autoimmune diseases: impairment B cell maturation in mice lacking BlyS. Immunity (2001) 15:280-302.
   Web of Science ®Google Scholar
• DALL’ERA M, CHAKRAVARTY E, GENOVESE M et al.: A phase Ib trial of atacicept (TACI-Ig) in patients with systemic lupus erythematosus. Am. Coll. Rheumatol. (2006)
   Google Scholar
• MUNAFO A, ROSSIER C, PETER N et al.: Results from phase Ib study of TACI-Ig in rheumatoid arthritis (RA) patients. European League Against Rheumatism (2006).
   Google Scholar
• KHAW B, TEKABE Y, JOHNSON LL: Imaging experimental atherosclerosic lesions in ApoE knockout mice: enhanced targeting with Z2D3-anti-DTPA bispecific antibody and 99mTc-labeled negatively changed polymers. J. Nucl. Med. (2006) 47(5):868-876.
   PubMed Web of Science ®Google Scholar
• RAEDLER T, KNABLE M, JONES D et al.: Central muscarinic acetylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacology (2006) 28:1531-1537.
   Google Scholar
• JADVAR H: Highlights of the Radiological Society of North America 91st scientific assembly and annual meeting. Hybrid imaging: daybreak for a new radiology. Radiological Society of North America (2005).
   Google Scholar
• DUMONT F: The interleukin-1 families of cytokines and receptors: therapeutic potential for immunomodulation and the treatment of inflammatory disorders. Expert Opin. Ther. Patents (2006) 16(7):879-912.
   Web of Science ®Google Scholar
• ABDERRAHIM H, WOJCIK J, MARTINELLI-BONESCHI F et al.: Genetics of multiple sclerosis, the role of MHC alleles and the effect of disease heterogeneity. European Congress for Treatment and Research in Multiple Sclerosis (2006).
   Google Scholar
• Conference report “Research-industry cooperation in EU RTD programs.” (2004):1-22.
   Google Scholar
• PASTEUR L: Quelques Réflexions sur la science en France. Op. cit. – VII tome (1871):211.
   Google Scholar